Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

BACKGROUND: Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with relapsed or progressive advanced malignancies and varying degrees of impaired hepat...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jennifer, Plummer, Ruth, Bauer, Todd M., Anthony, Stephen, Sarantopoulos, John, De Vos, Filip, White, Mike, Schupp, Marco, Ou, Ying, Vaishampayan, Ulka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627448/
https://www.ncbi.nlm.nih.gov/pubmed/29026685
http://dx.doi.org/10.1186/s40164-017-0086-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627448/
https://www.ncbi.nlm.nih.gov/pubmed/29026685
http://dx.doi.org/10.1186/s40164-017-0086-1

Ejemplares similares